STAT Plus: Bellus Health suffers setback with clinical trial failure of chronic cough drug
Bellus Health is reporting Monday negative results from a mid-stage clinical trial of its experimental pill for chronic cough — a disappointing outcome that is forcing the Canadian drug maker to rethink and prolong development plans.
Merck, Bayer and Shionogi are all working on similar drugs to treat chronic cough, so they benefit from Bellus’ setback. In February, Merck reported positive results from a Phase 3 clinical trial.
